Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Insulet Resumes Pivotal Study of its Next-Generation Product - Omnipod, Powered by Horizon™
ACTON, Mass. --(BUSINESS WIRE)--Jun. 5, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced it has resumed its pivotal study of Omnipod, Powered by Horizon™, the
View HTML
Toggle Summary Insulet to Present at Upcoming Investor Conferences
ACTON, Mass. --(BUSINESS WIRE)--May 28, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at two upcoming virtual investor conferences: The Piper
View HTML
Toggle Summary Insulet Corporation Announces Pricing of $500 Million Public Offering of Common Stock
ACTON, Mass. --(BUSINESS WIRE)--May 12, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), a global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced the pricing of its $500 million common stock registered
View HTML
Toggle Summary Insulet Corporation Announces Plans for Public Offering of Common Stock
ACTON, Mass. --(BUSINESS WIRE)--May 12, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), a global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced that it plans to make an offering of $500 million of its
View HTML
Toggle Summary Presentation for Insulet Public Offering of Common Stock
Toggle Summary Insulet to Present at Upcoming Investor Conferences
ACTON, Mass. --(BUSINESS WIRE)--May 8, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at two upcoming investor conferences: The BofA Securities
View HTML
Toggle Summary Insulet Reports First Quarter 2020 Revenue Increase of 24% Year-Over-Year
Includes Total Omnipod Revenue Growth of 33% ACTON, Mass. --(BUSINESS WIRE)--May 7, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced financial
View HTML
Toggle Summary Insulet Expands its U.S. Financial Assistance Program for Current Users Impacted by COVID-19
ACTON, Mass --(BUSINESS WIRE)--Apr. 16, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced an expansion of its U.S. financial assistance program for current
View HTML
Toggle Summary Insulet to Announce First Quarter 2020 Financial Results on May 7, 2020
ACTON, Mass. --(BUSINESS WIRE)--Apr. 6, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results for the first quarter of 2020 on
View HTML
Toggle Summary Insulet’s Omnipod DASH™ System Voted 2020 Product of the Year in Health Systems Category by 40,000 U.S. Consumers
Product Innovation Award Further Validates Omnipod as a Consumer Preferred Solution ACTON, Mass. --(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® DASH Insulin Management System (Omnipod DASH ™
View HTML
Toggle Summary Insulet Provides Update on Pivotal Study of Omnipod Horizon™
ACTON, Mass. --(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that it plans to pause the pivotal study of the Omnipod Horizon™ Automated Glucose
View HTML
Toggle Summary Insulet Reports Full Year 2019 Revenue of $738.2 Million, an Increase of 31%, and Fourth Quarter 2019 Revenue of $209.4 Million, an Increase of 27% Year-Over-Year
ACTON, Mass. --(BUSINESS WIRE)--Feb. 25, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced financial results for the three months and full year
View HTML
Toggle Summary Insulet to Present at Upcoming Investor Conferences
ACTON, Mass. --(BUSINESS WIRE)--Feb. 24, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at four upcoming investor conferences (all times below are
View HTML
Toggle Summary Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System
First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control Initially compatible with Dexcom G6 CGM, with no fingersticks* required Integration with the next generation Dexcom G7 CGM system, once available SAN DIEGO & ACTON, Mass.
View HTML
Toggle Summary Abbott and Insulet Partner to Integrate Next-Generation Glucose Sensing and Automated Insulin Delivery Technologies for Seamless Diabetes Care
- Collaboration will combine Abbott's leading continuous glucose monitoring (CGM) technology with Insulet's Omnipod Horizon™ Automated Insulin Delivery System to offer an accurate, easy-to-use, integrated digital health platform - Integrated technology will provide people living with diabetes
View HTML